Drug intelligence / Profile preview

CJ-30059

Development stage: Phase 1
Lead developer: HK inno.N Corporation
Modality: Small Molecules
Administration: Oral

Overview

CJ-30059 is a small molecule drug candidate developed by HK INNO.N CORPORATION. Its precise mechanism of action is currently unknown. The compound has been evaluated in at least one clinical trial designed to assess its bioequivalence, including comparison with candesartan, an angiotensin II receptor blocker used for hypertension. No FDA designation or approval status has been reported for this agent.

Targets

ADORA2A (Adenosine A₂A Receptor)DCLK1 (Doublecortin-like kinase 1)PTPN1 (Protein tyrosine phosphatase 1B)

Beyond the preview

Go deeper on CJ-30059.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJ-30059.

Explore the full profile